Key Drivers
- Profitability rebound
- Strong cash flow
- High leverage
AIAI Summary
JAZZ is no longer a stable cash-flow story but a more binary execution-and-catalyst play: strong margin/EPS growth and durable neuroscience sales support the base, yet the stock now hinges on Ziihera approval/commercial execution and whether oncology setbacks like Zepzelca can be offset, making the current valuation vulnerable if milestones slip.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Profitability rebound
- •Strong cash flow
- •High leverage
Jazz showed a strong Q1 FY2026 rebound in profitability and cash generation with solid liquidity, but leverage, intangibles-heavy assets, and a still-rich valuation remain key risks.
Price Behavior
Key Price Behavior Insights:
- •Breakout above 240
- •Short-term overbought
- •Rising support levels
JAZZ has broken above the $240 breakout zone and remains constructive, but after a sharp run to the top of its last month range it is short-term overbought and vulnerable to a pullback unless it holds $237-$238 and then $230-$231.
Quick rally from $224.66 to $243.47 after late-June strength signals elevated short-term momentum
Sentiment & News
Key News Insights:
- •Oncology momentum
- •Zepzelca setback
- •Xywav data
Jazz Pharmaceuticals drew support from bullish valuation/technical commentary and oncology collaboration momentum, but Zepzelca trial misses temper the outlook despite continued Xywav data progress.
Overall, the news is mildly mixed for JAZZ, with collaboration and pipeline upside offset by late-stage trial disappointment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings